Liquid chromatography-electrospray tandem mass spectrometric assay suitable for quantitation of YM155, a novel small-molecule survivin suppressant, in dog plasma

被引:9
作者
Minematsu, Tsuyoshi [1 ]
Felder, Laurie [2 ]
Oppeneer, Todd [2 ]
Sakazume, Masashi [3 ]
Oikawa, Keishi [4 ]
Hashimoto, Tadashi [1 ]
Usui, Takashi [1 ]
Kamimura, Hidetaka [1 ]
机构
[1] Astellas Pharma Inc, Drug Metab Res Labs, Itabashi Ku, Tokyo 1748511, Japan
[2] Covance Labs Inc, Madison, WI USA
[3] Astellas Res Technol Co Ltd, Tokyo, Japan
[4] Astellas Pharma Inc, Clin Pharmacol, Tokyo, Japan
关键词
YM155; bioanalytical method; LC-MS/MS; validation; pharmacokinetics; dog plasma;
D O I
10.1002/bmc.996
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
This paper describes a sensitive and selective liquid chromatography with tandem mass spectrometry (LC-MS/MS) method for determination of the novel survivin suppressant YM155, 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazolium, which is developed for the treatment of solid tumors. This method uses a liquid-liquid extraction from 0.25 mL of dog plasma. LC separation was carried out on a Genesis Silica column (50 mm x 3.0 mm i.d.) at a flow-rate of 0.5 mL/min. Compounds were eluted using a mobile phase of 5 mm ammonium acetate and 0.1% formic acid in water-0.1% formic acid in acetonitrile, 17:83 (v/v). MS/MS detection was carried out with an MDS-Sciex API3000 triple quadrupole mass spectrometer in positive electrospray ionization mode. The standard curve was linear from 0.05 to 50 ng/mL (r >= 0.9968). The lower limit of quantitation was 0.05 ng/mL. Good intra- and inter-day assay precision (within 7.4% RSD) and accuracy (within +/- 12.3%) were obtained. The extraction recovery was 66.2%. The method was successfully applied to preelinical pharmacokinetic studies in dogs. Copyright (c) 2008 John Wiley & Sons, Ltd.
引用
收藏
页码:763 / 769
页数:7
相关论文
共 21 条
  • [11] Broad spectrum and potent anti tumor activity of YM155, a novel small molecule survivin suppressant, against a large scale panel of human tumor cell lines
    Nakahara, T.
    Takeuchi, M.
    Kita, A.
    Yamanaka, K.
    Koutoku, H.
    Kinoyama, I.
    Matsuhisa, A.
    Sasamata, M.
    [J]. EJC SUPPLEMENTS, 2006, 4 (12): : 122 - 122
  • [12] YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts
    Nakahara, Takahito
    Takeuchi, Masahiro
    Kinoyama, Isao
    Minematsu, Tsuyoshi
    Shirasuna, Kenna
    Matsuhisa, Akira
    Kita, Aya
    Tominaga, Fumiko
    Yamanaka, Kentaro
    Kudoh, Masafumi
    Sasamata, Masao
    [J]. CANCER RESEARCH, 2007, 67 (17) : 8014 - 8021
  • [13] Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin
    O'Connor, DS
    Grossman, D
    Plescia, J
    Li, FZ
    Zhang, H
    Villa, A
    Tognin, S
    Marchisio, PC
    Altieri, DC
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (24) : 13103 - 13107
  • [14] The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral-inhibitor of apoptosis proteins
    Rothe, M
    Pan, MG
    Henzel, WJ
    Ayres, TM
    Goeddel, DV
    [J]. CELL, 1995, 83 (07) : 1243 - 1252
  • [15] The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases
    Roy, N
    Deveraux, QL
    Takahashi, R
    Salvesen, GS
    Reed, JC
    [J]. EMBO JOURNAL, 1997, 16 (23) : 6914 - 6925
  • [16] Expression of the antiapoptosis gene, Survivin, predicts death from recurrent colorectal carcinoma
    Sarela, AI
    Macadam, RCA
    Farmery, SM
    Markham, AF
    Guillou, PJ
    [J]. GUT, 2000, 46 (05) : 645 - 650
  • [17] Tamm I, 1998, CANCER RES, V58, P5315
  • [18] Tanaka K, 2000, CLIN CANCER RES, V6, P127
  • [19] Tolcher AW, 2006, J CLIN ONCOL, V24, p124S
  • [20] Verdecia MA, 2000, NAT STRUCT BIOL, V7, P602